3/5
09:01 am
tnya
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics [Yahoo! Finance]
High
Report
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics [Yahoo! Finance]
3/5
08:30 am
tnya
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics
High
Report
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics
3/2
04:05 pm
tnya
Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026
Medium
Report
Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026
1/23
09:39 pm
tnya
Assessing Tenaya Therapeutics (TNYA) Valuation After Its US$60 Million Capital Raise And Extended Cash Runway [Yahoo! Finance]
Medium
Report
Assessing Tenaya Therapeutics (TNYA) Valuation After Its US$60 Million Capital Raise And Extended Cash Runway [Yahoo! Finance]
1/19
08:26 am
tnya
Morgan Stanley Backs Tenaya Therapeutics (TNYA) as SMID-Cap Biotech Primed to Outperform in 2026 [Yahoo! Finance]
Medium
Report
Morgan Stanley Backs Tenaya Therapeutics (TNYA) as SMID-Cap Biotech Primed to Outperform in 2026 [Yahoo! Finance]
1/9
08:30 am
tnya
Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones
Low
Report
Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones
1/8
10:05 am
tnya
Tenaya Therapeutics (NASDAQ:TNYA) was given a new $2.00 price target on by analysts at Morgan Stanley.
Low
Report
Tenaya Therapeutics (NASDAQ:TNYA) was given a new $2.00 price target on by analysts at Morgan Stanley.
12/18
08:43 am
tnya
Tenaya Therapeutics (NASDAQ:TNYA) had its "buy" rating reaffirmed by analysts at Canaccord Genuity Group Inc..
Medium
Report
Tenaya Therapeutics (NASDAQ:TNYA) had its "buy" rating reaffirmed by analysts at Canaccord Genuity Group Inc..
12/14
01:35 pm
tnya
Tenaya Therapeutics (TNYA) Is Down 39.7% After Cardiac Gene Therapy Milestones And $60M Fundraise - What's Changed [Yahoo! Finance]
Medium
Report
Tenaya Therapeutics (TNYA) Is Down 39.7% After Cardiac Gene Therapy Milestones And $60M Fundraise - What's Changed [Yahoo! Finance]
12/12
11:24 am
tnya
Tenaya Therapeutics (NASDAQ:TNYA) had its price target lowered by analysts at HC Wainwright from $5.00 to $3.00. They now have a "buy" rating on the stock.
Medium
Report
Tenaya Therapeutics (NASDAQ:TNYA) had its price target lowered by analysts at HC Wainwright from $5.00 to $3.00. They now have a "buy" rating on the stock.
12/12
08:18 am
tnya
Tenaya Therapeutics (NASDAQ:TNYA) had its price target lowered by analysts at Chardan Capital from $9.00 to $8.00. They now have a "buy" rating on the stock.
High
Report
Tenaya Therapeutics (NASDAQ:TNYA) had its price target lowered by analysts at Chardan Capital from $9.00 to $8.00. They now have a "buy" rating on the stock.
12/12
12:16 am
tnya
Tenaya Therapeutics Announces Pricing of Public Offering
High
Report
Tenaya Therapeutics Announces Pricing of Public Offering
12/11
04:47 pm
tnya
Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy [Yahoo! Finance]
High
Report
Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy [Yahoo! Finance]
12/11
04:47 pm
tnya
Tenaya Therapeutics Announces Proposed Public Offering [Yahoo! Finance]
High
Report
Tenaya Therapeutics Announces Proposed Public Offering [Yahoo! Finance]
12/11
04:47 pm
tnya
Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC [Yahoo! Finance]
High
Report
Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC [Yahoo! Finance]
12/11
04:02 pm
tnya
Tenaya Therapeutics Announces Proposed Public Offering
High
Report
Tenaya Therapeutics Announces Proposed Public Offering
12/11
04:01 pm
tnya
Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy
High
Report
Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy
12/11
04:01 pm
tnya
Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC
High
Report
Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC
12/4
11:57 pm
tnya
Tenaya Therapeutics: Risky But Promising Cardiac Gene Platform [Seeking Alpha]
Neutral
Report
Tenaya Therapeutics: Risky But Promising Cardiac Gene Platform [Seeking Alpha]